Search research articles
Contact Us
Filters
Showing results (1-10 of 42) with videos related to
Page
of 5
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease
|
August 9, 2020
Nebulized Therapies in COPD: Past, Present, and the Future
Igor Z Barjaktarevic, Aaron P Milstone
Therapeutic Advances in Respiratory Disease
|
November 10, 2020
The use of nebulized pharmacotherapies during the COVID-19 pandemic
Sanjay Sethi, Igor Z Barjaktarevic, Donald P Tashkin
Journal of Immunology Research
|
July 23, 2016
The Role of Interleukin-23 in the Early Development of Emphysema in HIV1(+) Smokers
Igor Z Barjaktarevic, Ronald G Crystal, Robert J Kaner
Seminars in Respiratory and Critical Care Medicine
|
July 5, 2024
Impact of Marijuana Use on Lung Health
Joanne M Bando, Donald P Tashkin, Igor Z Barjaktarevic
International Journal of Chronic Obstructive Pulmonary Disease
|
August 6, 2015
Positioning new pharmacotherapies for COPD
Igor Z Barjaktarevic, Anthony F Arredondo, Christopher B Cooper
Chest
|
March 6, 2013
Organizing pneumonia as a side effect of ipilimumab treatment of melanoma
Igor Z Barjaktarevic, Nida Qadir, Anu Suri, et al.
Journal of Intensive Care Medicine
|
August 8, 2022
Outcomes and Prognostic Factors of Pulmonary Hypertension Patients Undergoing Emergent Endotracheal Intubation
Andrew W Hong, William Toppen, Joyce Lee, et al.
Annals of the American Thoracic Society
|
August 20, 2024
Duration and Frequency of Spirometry Needed to Accurately Reflect Annualized Change of FEV<sub>1</sub> in Chronic Obstructive Pulmonary Disease
Jared D Wilkinson, Holly Wilhalme, Christopher B Cooper, et al.
Chest
|
August 28, 2024
Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD
Frank C Sciurba, Stephanie A Christenson, Tara Rheault, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 26, 2023
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)
Antonio Anzueto, Igor Z Barjaktarevic, Thomas M Siler, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 42) with videos related to
Sort By:
Page
of 5
International Journal of Chronic Obstructive Pulmonary Disease
|
August 9, 2020
Nebulized Therapies in COPD: Past, Present, and the Future
Igor Z Barjaktarevic, Aaron P Milstone
Therapeutic Advances in Respiratory Disease
|
November 10, 2020
The use of nebulized pharmacotherapies during the COVID-19 pandemic
Sanjay Sethi, Igor Z Barjaktarevic, Donald P Tashkin
Journal of Immunology Research
|
July 23, 2016
The Role of Interleukin-23 in the Early Development of Emphysema in HIV1(+) Smokers
Igor Z Barjaktarevic, Ronald G Crystal, Robert J Kaner
Seminars in Respiratory and Critical Care Medicine
|
July 5, 2024
Impact of Marijuana Use on Lung Health
Joanne M Bando, Donald P Tashkin, Igor Z Barjaktarevic
International Journal of Chronic Obstructive Pulmonary Disease
|
August 6, 2015
Positioning new pharmacotherapies for COPD
Igor Z Barjaktarevic, Anthony F Arredondo, Christopher B Cooper
Chest
|
March 6, 2013
Organizing pneumonia as a side effect of ipilimumab treatment of melanoma
Igor Z Barjaktarevic, Nida Qadir, Anu Suri, et al.
Journal of Intensive Care Medicine
|
August 8, 2022
Outcomes and Prognostic Factors of Pulmonary Hypertension Patients Undergoing Emergent Endotracheal Intubation
Andrew W Hong, William Toppen, Joyce Lee, et al.
Annals of the American Thoracic Society
|
August 20, 2024
Duration and Frequency of Spirometry Needed to Accurately Reflect Annualized Change of FEV<sub>1</sub> in Chronic Obstructive Pulmonary Disease
Jared D Wilkinson, Holly Wilhalme, Christopher B Cooper, et al.
Chest
|
August 28, 2024
Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD
Frank C Sciurba, Stephanie A Christenson, Tara Rheault, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 26, 2023
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)
Antonio Anzueto, Igor Z Barjaktarevic, Thomas M Siler, et al.
Page
of 5